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Abstract
Neurodegenerative diseases likely share common underlying pathobiology. Although prior work has identified
susceptibility loci associated with various dementias, few, if any, studies have systematically evaluated shared genetic
risk across several neurodegenerative diseases. Using genome-wide association data from large studies (total n =
82,337 cases and controls), we utilized a previously validated approach to identify genetic overlap and reveal common
pathways between progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), Parkinson’s disease (PD) and
Alzheimer’s disease (AD). In addition to the MAPT H1 haplotype, we identified a variant near the chemokine receptor
CXCR4 that was jointly associated with increased risk for PSP and PD. Using bioinformatics tools, we found strong
physical interactions between CXCR4 and four microglia related genes, namely CXCL12, TLR2, RALB, and CCR5.
Evaluating gene expression from post-mortem brain tissue, we found that expression of CXCR4 and microglial genes
functionally related to CXCR4 was dysregulated across a number of neurodegenerative diseases. Furthermore, in a
mouse model of tauopathy, expression of CXCR4 and functionally associated genes was significantly altered in regions
of the mouse brain that accumulate neurofibrillary tangles most robustly. Beyond MAPT, we show dysregulation of
CXCR4 expression in PSP, PD, and FTD brains, and mouse models of tau pathology. Our multi-modal findings suggest
that abnormal signaling across a ‘network’ of microglial genes may contribute to neurodegeneration and may have
potential implications for clinical trials targeting immune dysfunction in patients with neurodegenerative diseases.
Introduction
Uncovering the shared genetic architecture across
neurodegenerative diseases may elucidate underlying
common disease mechanisms and promote early disease
detection and intervention strategies. Progressive supra-
nuclear palsy (PSP), frontotemporal dementia (FTD),
Parkinson’s disease (PD) and Alzheimer’s disease (AD) are
age-associated neurodegenerative disorders placing a
large emotional and financial impact on patients and
society. Despite variable clinical presentation, PSP, AD
and FTD are characterized by abnormal deposition of tau
protein in neurons and/or glia in the frontal, temporal,
and insular cortical gray matter and hindbrain1,2. PSP is
associated with 4-repeat (4R) tau inclusions1,3; FTD is
characterized by 3-repeat (3R)-only, 4R-only, or mixed
(3R and 4R) tau inclusions or TAR DNA-binding protein
43 aggregates4; and AD is characterized by extracellular
amyloid plaques and neurofibrillary tangles (NFTs)
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composed of hyperphosphorylated tau (mixed 3R and 4R
tau inclusions)5,6. While PD is classically characterized by
alpha-synuclein deposits, recent studies support the role
of tau and NFTs in modifying PD clinical sympotoma-
tology and disease risk7–9. Prior work has shown that PSP
shares overlapping pathobiology with FTD, AD, and
PD10–13.
Genome-wide association studies (GWAS) and candi-
date gene studies have identified single nucleotide poly-
morphisms (SNPs) within the H1 haplotype in MAPT
locus (which encodes tau) that increase risk for PSP, FTD,
AD, and PD14–19. However, beyond MAPT, the extent of
genetic overlap across these diseases and its relationship
with common pathogenic processes observed in PSP,
FTD, AD, and PD remain poorly understood.
Genomic studies evaluating shared risk among numer-
ous phenotypes or diseases suggest genetic pleiotropy,
where a single gene or genetic variant may impact dif-
ferent traits17–20. The recent proliferation of GWAS data
for rare disorders like PSP paired with large studies of
more common diseases such as AD, PD, and FTD pro-
vides unique opportunities to gain statistical power and
identify risk loci which may not have otherwise been
identified in the original GWAS study. Further, it allows
for the systematic evaluation of genetic overlap across
different disorders, thereby informing shared biological
pathways and processes commonly altered in both con-
ditions. Here, using previously validated methods20–23, we
assessed shared genetic risk across PSP, PD, FTD, and
AD. We then applied molecular and bioinformatic tools




We obtained publicly available PSP-GWAS summary
statistic data from the NIA Genetics of Alzheimer’s Dis-
ease Storage Site, which consisted of 1114 individuals with
PSP (cases) and 3247 controls (stage 1) at 531,451 SNPs
(Table 1, for additional details see18). In this study, we
focused on stage 1 of the PSP GWAS dataset. Individuals
were diagnosed with PSP according to NINDS criteria24.
We evaluated complete summary statistic GWAS data
from clinically diagnosed FTD, AD, and PD. The Inter-
national Parkinson’s Disease Genetics Consortium
(IPDGC) provided PD-GWAS summary statistic data.
The IPDGC cohort consists of 5333 cases and 12,019
controls with genotype or imputed data at 7,689,524 SNPs
(Table 1, for additional details see9). The International
FTD GWAS Consortium (IFGC) provided phase 1 FTD-
GWAS summary statistic data, which consisted of 2154
FTD cases and 4308 controls with genotypes or imputed
data at 6,026,384 SNPs (Table 1, for additional details
see25 and Supplemental Information). The FTD dataset
included multiple subtypes within the FTD spectrum:
bvFTD, semantic dementia, progressive non-fluent apha-
sia, and FTD overlapping with motor neuron disease. We
obtained publicly available, AD-GWAS summary statistic
data from the International Genomics of Alzheimer’s
Disease Project (IGAP Stage 1) (see Supplemental Infor-
mation). The IGAP Stage 1 cohort consists of 17,008 AD
cases and 37,154 controls with genotyped or imputed data
at 7,055,881 SNPs (Table 1, for additional details see26 and
Supplemental Information). All four cohorts were pri-
marily of European ancestry and the studies’ authors
controlled for population stratification using a principal
components analysis approach. Inclusion/exclusion cri-
teria were established by each study’s authors; please see
the publications provided in Table 1 for additional details.
In each study, informed consent was obtained from all
subjects. Institutional approval was provided by each
study’s respective committee.
Identification of shared risk loci—conjunction FDR
We evaluated SNPs associating with PSP (Phase 1), FTD
(IFGC Phase 1), AD (IGAP Stage 1) and PD (IPDGC
Phase 1) using techniques for evaluating genetic pleio-
tropy (for additional details see Supplemental Information
and21,23). Briefly, for two phenotypes A and B, pleiotropic
‘enrichment’ of phenotype A with phenotype B exists if
the effect sizes of the genetic associations with phenotype
A become larger as a function of increased association
with phenotype B. For each phenotype, Z scores were
derived for each SNP association given the Wald statistics.
We then corrected the Z scores for potential genomic
inflation(for additional methodological details used in our
study, see Supplemental Information and see27 for addi-
tional information on genomic inflation). To assess
enrichment, we constructed fold-enrichment plots of
nominal –log10(p) values for all PSP SNPs and a subset of
SNPs determined by the significance of their association
with AD, FTD, and PD. Under expected null, the average
effect sizes given a group of SNPs would be the same
Table 1 Pleiotropy analysis cohort descriptions
Disease/Trait Total N # SNPs Reference






Alzheimer’s disease (AD)—Phase 1 54,162 7,055,881 26
Parkinson’s disease (PD) 17,352 7,689,524 9
Cohort descriptions with identifying details of the publishing study are provided
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when the conditioned effect increases. Therefore, in fold-
enrichment plots, enrichment is indicated by an upward
deflection of the curve for phenotype A if it shares genetic
effects with phenotype B. To assess for polygenic effects
below the standard GWAS significance threshold, we
focused the fold-enrichment plots on SNPs with nominal
–log10(p)< 7.3 (corresponding to p-value> 5× 10
−8).
The enrichment can be interpreted in terms of true dis-
covery rate (TDR= 1−False Discovery Rate [FDR]) (for
additional details see Supplemental Information and28).
To identify specific loci involved in both PSP and AD,
FTD or PD, we computed conjunction FDR21–23. Con-
junction FDR, denoted by FDRtrait1& trait2 is defined as the
posterior probability that a SNP is null for either pheno-
type or both simultaneously, given the p-values for both
traits are as small, or smaller, than the observed p-values.
A conservative estimate of the conjunction FDR is given
by the maximum statistic in taking the maximum of
FDRtrait1|trait2 and FDR trait2|trait1 (for additional details see
Supplemental Information and21). We used an overall
FDR threshold of <0.05. To visualize the results of our
conjunction FDR analysis, we constructed Manhattan
plots based on the ranking of conjunction FDR to illus-
trate the genomic location of the pleiotropic loci. Rather
than representing novel risk variants where replication is
needed in independent datasets, conjunction FDR pin-
points genetic variants jointly associated with two or more
phenotypes/diseases and in this context, ‘replication’ may
not be meaningful21.
Functional evaluation of shared risk loci
To assess whether the PSP, FTD, AD, and PD over-
lapping SNPs modify gene expression, we evaluated cis-
expression quantitative trait loci (eQTLs, DNA sequence
variants that influence the expression level of one or more
genes) in a publicly available dataset from 134 neuro-
pathologically confirmed normal control brains (UKBEC,
http://braineac.org/)29 and validated these eQTLs in the
GTex dataset30. We also evaluated eQTLs using a blood-
based dataset31. We applied an analysis of covariance
(ANCOVA) to test for association between genotypes and
gene expression. SNPs were tested using an additive
model.
Network-based functional association analyses
To evaluate potential protein and genetic interactions,
co-expression, co-localization and protein domain simi-
larity for the pleiotropic genes, we used GeneMANIA
(www.genemania.org), an online web-portal for bioinfor-
matic assessment of gene networks32. In addition to
visualizing the composite gene network, we also assessed
the weights of individual components within the
network33.
Gene expression alterations in PSP, PD, and FTD brains
To determine whether pleiotropic genes were differen-
tially expressed in PSP, PD, and FTD brain tissue, we
analyzed gene expression of pleiotropic genes in publically
available datasets. We analyzed gene expression data
from: (1) the temporal cortex and cerebellum of 80 con-
trol and 84 PSP brains (syn5550404); (2) the frontal cor-
tex; hippocampus and cerebellum of 11 controls and 17
FTLD-U (7 brains with or 10 brains without progranulin
(GRN) mutations) (Gene Expression Omnibus (GEO)
dataset GSE13162)34; and (3) the substantia nigra of 23
control and 22 PD brains (GEO dataset GSE7621)35.
Evaluating gene expression of pleiotropic loci in tau
transgenic mouse models
We evaluated gene expression profiles for the nearest
genes associated with our shared risk loci using publicly
available P301L-tau transgenic mouse model (mutant
human MAPT gene) from Mouseac (www.mouseac.
org)36. Briefly, microarray gene expression data was col-
lected from three brain regions (cortex, hippocampus and
cerebellum) from wild-type and P301L-tau transgenic
mice. Gene expression levels were log transformed and
expressed as a function of age. The presence of NFT
pathology was evaluated and scored as previously repor-
ted by immunohistochemistry36. Using repeated measures
ANOVAs within the hippocampus, cortex and cere-
bellum, we examined whether gene expression levels of
PSP, FTD, AD, and PD variants are significantly different
between the P301L-tau transgenic and wild-type mice,
across 2, 4, 8 and 18 months of age. To maximize our
ability to detect an effect, we used all expression data
available for each line of mice and age grouping. As our
data was publicly available, there was no randomization or
blinding of the data. Please see (www.mouseac.org)36 for
exact sample sizes used in each analysis and additional
information on the mouse data used in this study.
Code availability
The code used to conduct pleiotropy analyses is not yet
publicly available. Please contact the authors with any
inquiries related to the code.
Results
Selective shared genetic risk between PSP, PD, and FTD
We observed SNP enrichment for PSP SNPs across
different levels of significance of association with FTD
(Fig. 1a). Using progressively stringent p-value thresholds
for PSP SNPs (i.e., increasing values of nominal –log10(p)),
we found up to 150-fold genetic enrichment using FTD
and lower, but still notable, enrichment in PD (Figs. 1a, b).
In contrast, we found minimal or no enrichment in PSP
SNPs as a function of AD (Figs. 1a, b).
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At a conjunction FDR< 0.05, we identified 2 SNPs that
were associated with increased risk for both PSP and PD
(Table 2, Fig. 1b): rs749873 (intergenic; closest gene=
CXCR4, on chr2, minimum conjunction FDR= 0.01;
Supplemental Fig. 1a) and rs11012 (UTR-3; closest gene
= PLEKHM1 withinMAPT region on chr 17, PSP p-value
= 4.9× 10−39, minimum conjunction FDR= 9.3× 10−9).
CXCR4 is a chemokine receptor implicated in immune
processes, microglia recruitment, neuronal guidance,
neural stem cell proliferation, and neurodevelopmental
processes37–40. At a conjunction FDR< 0.05, we identified
1 SNP that was associated with increased risk for both
PSP and FTD (Table 2, Fig. 1b): rs199533 (exonic; closest
gene=NSF within MAPT region on chr 17, PSP p-value
= 3.5× 10−41, minimum conjunction FDR= 9.3× 10−9;
Supplemental Fig. 1b). Notably, rs11012 and rs199533 is
Fig. 1 Shared genetic risk across PSP, AD, FTD and PD a Fold enrichment plots of enrichment vs. nominal −log10 p-values (corrected for inflation)
in progressive supranuclear palsy (PSP) below the standard GWAS threshold of p < 5 × 10-8 as a function of significance of association with
Alzheimer’s disease (AD, panel A), frontotemporal dementia (FTD, panel B) and Parkinson’s disease (PD, panel C) at the level of −log10(p)≥ 0,
−log10(p)≥ 1, −log10(p)≥ 2 corresponding to p≤ 1, p≤ 0.1, p≤ 0.01, respectively. Blue line indicates all SNPs. b “Conjunction” Manhattan plot of
conjunction and conditional –log10 (FDR) values for progressive supranuclear palsy (PSP) given Alzheimer’s disease (AD; PSP|AD, teal), frontotemporal
dementia (PSP; PSP|FTD, orange) and Parkinson’s disease (PD; PSP|PD, red). SNPs with conditional and conjunction –log10 FDR > 1.3 (i.e., FDR < 0.05)
are shown with large points. A black line around the large points indicates the most significant SNP in each LD block and this SNP was annotated
with the closest gene, which is listed above the symbols in each locus. c Network interaction graph illustrating physical interactions, co-expression,
predicted, pathway, co-localization, gene interactions and shared protein domains for CXCR4 and MAPT. Network plot was generated from
GeneMANIA (www.genemania.org)
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in strong linkage disequilibrium (LD) with SNP
rs1800547, which tags the H1 haplotype of MAPT
(rs11012 pairwise D’= 0.96, r2= 0.71; rs199533 pairwise
D’= 1, r2= 0.94). The H1 haplotype of MAPT has been
implicated in risk for both PSP, PD, and FTD18,19. In
contrast to PSP and PD as well as PSP and FTD, we found
no significant overlapping loci between PSP and AD.
Expression quantitative trait loci (eQTL) and gene
expression analyses
Consistent with our previous findings, rs749873 was
associated with expression of MCM6 within the CXCR4
locus in human brains and with CXCR4 expression in
whole blood41. In the human CNS, rs749873 modifies
MCM6 expression in the tibial nerve41. Interestingly,
rs749873 is in high LD with rs2011946 (r2= 0.91; D’= 1),
a SNP we previously reported to be shared across PSP and
corticobasal degeneration (CBD)41. As previously repor-
ted, rs199533 was significantly associated with MAPT
expression in human brains (p= 2× 10−12)41.
Protein-protein and co-expression networks for MAPT and
CXCR4
Using GeneMANIA, we examined the proteins that
physically interact with and/or are co-expressed with
MAPT or CXCR4 (Fig. 1c). As previously reported41,
CXCR4 demonstrated the strongest physical interaction
with chemokine motif ligand 12 (CXCL12), toll-like
receptor 2 (TLR2), Ras-related protein-B (RALB) and
C–C chemokine receptor 5 (CCR5) (Fig. 1c) (Supple-
mental Table 1). CXCL12 is the ligand for CXCR442,43.
TLR2 encodes a toll-like receptor which is utilized by the
innate immune system to detect pathogenic material—it
is expressed on microglia as well as astrocytes and has
Table 2 Pleiotropy analysis results












rs749873 CXCR4 2 C T 0.01 PD 1.32E-04 6.66E-05 NA 0.48
rs199533 NSF 17 A G 9.27E-09 FTD 3.52E-41 1.07E-15 4.89E-05 0.01
Results from pleiotropy analyses are shown. For each SNP, the nearest gene, chromosome, reference allele, alternative allele, conjunction p-value, conjunction analysis,
and raw p-value from each of the four available GWAS is provided
Fig. 2 CXCR4 is differentially expressed in human neurodegenerative diseases and in mouse models of tauopathies a CXCR4 expression in
neuropathologically normal tissue compared to PSP. b CXCR4 expression in neuropathologically normal tissue compared to sporadic FTD and FTD
due to GRN mutations. (c) CXCR4 expression in neuropathologically normal tissue compared to PD. d-e Line plots illustrating CXCR4 gene expression
in tau transgenic (red line) and wild-type mice (black line) from 2 to 18 months of age in the d hippocampus. e Total tau pathology over time is also
illustrated
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been proposed as an inhibitor of neural progenitor cell
proliferation44. RALB is a small GTPase protein that
interacts with CXCL12 and is implicated in B-cell
migration45. CCR5 is a chemokine structurally related to
CXCR4 and modulates the migration of microglia and
blood brain barrier integrity46,47.
We found that MAPT showed robust physical interac-
tions with FKBP4 and STUB1 (Fig. 1c; Supplemental
Table 1). FKBP4 (also known as FKBP52) is a peptidyl-
prolyl isomerase which is involved in dynein interaction
and glucocorticoid receptor movement to the nucleus48.
STUB1 is a ubiquitin ligase with diverse functions that has
been implicated in AD49.
CXCR4 gene expression alterations in PSP, PD, and other
neurodegenerative disease brains
We next sought to determine whether CXCR4 is
differentially expressed in PSP, PD, and FTD brains.
We included FTD brain tissues in our analyses
because no SNP data for rs749873 was available for pri-
mary pleiotropy analysis in FTD, leaving open the possi-
bility that CXCR4 expression may be altered in FTD.
Compared with control brains, we found that CXCR4
was significantly upregulated in brains with a neuro-
pathological diagnosis of PSP and FTD, especially within
the cerebellum and hippocampus (Figs. 2a, b, Table 3).
Further, we found CXCR4 was also significantly upregu-
lated in PD cases (Fig. 2c; Table 3). We also evaluated
expression levels in PSP, FTD, and PD brains of the
four genes that showed strong physical interactions with
CXCR4 in our network analyses (CXCL12, TLR2, RALB
and CCR5; weighted connection with CXCR4> 0.25,
see above). We found that CXCL12 expression was
significantly dysregulated in PSP, and PD, but not in
FTD (Table 3). TLR2 levels were significantly altered
specifically in FTD. Of note, CCR5 levels were not
available for analysis. Neither MAPT or RALB expression
was significantly altered in PSP, FTD or PD brains relative
to controls (Table 3). Thus, our data suggest that
expression of CXCR4 and functionally associated
genes are significantly altered in regions of the brain
susceptible to different forms of neurodegenerative dis-
ease pathology.
Given the role of CXCR4 in astroglial signaling and
microglial activation50, we asked whether the observed
upregulation of CXCR4 in neurodegenerative disease was
driven by proliferation and activation of microglia in
response to neurodegenerative pathology. To assess this,
we evaluated whether commonly used markers of
microglial activation, namely TMEM119 and AIF151,52,
are also upregulated across neurodegenerative diseases.
Unlike CXCR4, across all evaluated brain regions within
PSP, FTD, and PD brains, we found no evidence for
altered TMEM119 and AIF1 expression (Table 3).
We next examined whether CXCR4 and AIF1 or
TMEM119 were significantly correlated in PSP, FTD, or
PD brains. We observed a significant correlation between
CXCR4 and AIF1 in FTD brains (combined FTD-GRN+
and FTD-GRN-: r2= 0.35 and p< 1× 10−4). As indicated
in Table 3, TMEM119 was not available within the FTD
dataset. In PSP brains, we found a marginally significant
correlation between CXCR4 and TMEM119 (PSP AIF1: r2
= 5.7× 10−4 and p= 0.83; PSP TMEM119: r2= 0.05 and
p= 0.05). However, CXCR4 and AIF1 or TMEM119 were
not correlated in PD brains (AIF: r2= 9.15× 10−5 and p
= 0.96 and TMEM119: r2= 0.10 and p= 0.10). Thus,
Table 3 Gene expression analysis in PSP, PD, and FTD brains
Diagnosis (Cohort) PSP FTD + GRN FTD-GRN PD
Tissue Type CRBL TC FC, HIP, CRBL FC, HIP, CRBL SN
N 84 84 7 10 22
Gene Name CXCR4 6.31 × 10−4 4.84 × 10−4 1.86 × 10−4 0.03 0.03
CXCL12 0.03 5.22 × 10−4 0.86 0.98 0.03
RALB 0.17 0.74 0.78 0.34 0.38
TLR2 0.37 0.23 1.07 × 10−3 0.02 0.85
MAPT 0.30 0.22 0.09 0.38 0.45
TMEM119 0.74 0.39 N/A N/A 0.27
AIF1 0.08 0.68 0.12 0.82 0.48
CRBL cerebellum, TC temporal cortex, SN substantia nigra, FC frontal cortex, HIP hippocampus
P-values from the gene expression analyses in pathologically confirmed cases are shown. When multiple probes were available for each gene, the p-value for the first
probe sorted by numerical order is provided. When multiple regions were used in an analysis, brain region was included as a covariate. For additional details on the
probes and effect sizes, please see the Supplemental Material. FTD + GRN—frontotemporal dementia caused by granulin mutations. FTD-GRN—sporadic
frontotemporal dementia
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these findings provide evidence suggesting that CXCR4
could contribute to neurodegeneration through microglial
activation as well as pathways beyond microglial
dysfunction.
CXCR4 expression is elevated in tau transgenic mouse
model
To assess whether CXCR4 expression is associated with
NFT pathology, we examined CXCR4 expression in brains
from a transgenic mouse model of tau aggregation (Tau-
P301L transgenic mice). Tau-P301L mice develop NFT
pathology in the hippocampus and neocortical regions by
6 months of age, while the cerebellum fails to develop
NFT pathology36,53. CXCR4 expression was significantly
elevated in the hippocampus (F= 10.3, p= 0.0023) in
Tau-P301L mice compared with wild-type mice (Fig. 2d).
In contrast, within the cerebellum (F= 0.001, p= 0.98)
and cortex (F= 1.06, p= 0.308), we found no difference
in CXCR4 expression between the Tau-P301L and wild-
type mice across any of the time points. MAPT expres-
sion, however, was not significantly altered in Tau-P301L
mice compared with wild-type in both the hippocampus
and cerebellum (Supplemental Fig. 2).
We additionally assessed expression levels of the four
genes (CXCL12, TLR2, RALB and CCR5) that showed
strong physical interactions with CXCR4 in our network
analyses (see Fig. 1c). Within the hippocampus and cor-
tex, TLR2 was significantly elevated over time (F= 7.07, p
= 1.35× 10−7 and F= 2.9, p= 8.19× 10−6, respectively)
and CCR5 expression was significantly decreased over
time (F= 0.3, p= 0.002) in Tau-P301L mice but not in
wild-type mice. Expression of CXCL12 (F= 0.19, p=
0.06) and RALB (F= 0.02, p= 0.09) were not significantly
altered in Tau-P301L mice (Supplemental Figs. 3–6).
Within the cerebellum, which remains free of tau aggre-
gates, we found no evidence for gene expression altera-
tions in CXCL12, TLR2, RALB, and CCR5 in Tau-P301L
mice compared with wild-type mice. Thus, expression of
CXCR4 and functionally associated genes is significantly
altered in regions of the mouse brain that accumulate
NFTs most robustly.
Finally, we evaluated whether TMEM119 and AIF1
expression is associated with CXCR4 expression and sig-
nificantly elevated within the hippocampus. Across all
evaluated time points (2, 4, 6, and 18 months) and within
wild-type and Tau-P301L transgenic mice, we found that
TMEM119 and AIF1 levels were significantly correlated
with CXCR4 expression specifically within the hippo-
campus (Supplemental Results). Similarly, predominantly
within the hippocampus, we found that TMEM119 and
AIF1 expression was elevated over time in Tau-P301L
mice compared with wild-type mice (Supplemental
Results). Evaluating CXCR4 associated genes, we found a
strong association between microglia and inflammation
related TLR2 and CCR5 expression and TMEM119 and
AIF1 expression, within the hippocampus, cortex and
cerebellum (Supplemental Results). In contrast, we found
no correlation between levels of CXCL12 and RALB with
TMEM119 or AIF1 (Supplemental Results). Together,
these findings suggest that innate immune system sig-
naling and microglial activation markers are associated
with neurodegeneration and tauopathy.
Discussion
We identified CXCR4 as a novel locus associated with
increased risk for both PSP and PD. Building on extensive
prior work, we also confirmed the role of variants within
MAPT in driving PSP, PD, and FTD risk. We found that
CXCR4 and functionally associated genes exhibit altered
expression across a number of neurodegenerative dis-
eases. In a mouse model of tauopathy, CXCR4 and func-
tionally associated genes were altered in the presence of
tau pathology. Together, our findings suggest that
alterations in expression of CXCR4 and associated
microglial genes may contribute to age-associated
neurodegeneration.
Utilizing GWAS summary statistics from multiple
neurodegenerative diseases, our results suggest that
shared genetic risk factors may underlie the pathobiolo-
gical processes occurring in PSP and PD. We found up to
a 150-fold enrichment in PSP as a function of FTD, lower
enrichment in PD, and no enrichment in AD. These
findings were unexpected given the established role of the
MAPT H1 haplotype in AD26. Despite the lack of strong
genetic association across these three neurodegenerative
diseases, we found that CXCR4 expression was altered in
brains that are pathologically confirmed for PSP, PD, and
FTD. Thus, these findings support our hypothesis that
these three neurodegenerative disorders share common
pathobiological pathways.
CXCR4 is a chemokine receptor protein with broad
regulatory functions in the immune system and neuro-
development39,40,43,54–56. CXCR4 has been shown to reg-
ulate neuronal guidance and apoptosis through astroglial
signaling and microglial activation50. Furthermore, it has
been shown that CXCR4 is involved in cell cycle regula-
tion through p53 and Rb57,58. Importantly, small mole-
cular agonists and antagonists to CXCR4 have been
described59. AMD3100 is an FDA-approved CXCR4
antagonist and a CXCR7 agonist that is commonly used to
enhance hematopoietic stem cell proliferation60.
Using a bioinformatics approach, we identified four
genes, namely CXCL12, TLR2, RALB and CCR5 that
showed a strong association with CXCR4. We additionally
found that expression of CXCR4 and functionally asso-
ciated genes were altered in multiple neurodegenerative
diseases and associated with hippocampal tau pathology
in transgenic mouse models. These findings suggest that a
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network of CXCR4 and associated genes may act in
concert to influence neurodegeneration.
Given that PSP, PD, and FTD are neuropathologically
characterized by degeneration in the midbrain, cere-
bellum, and (to a lesser extent) neocortical regions1,2,61,
our findings may suggest that subtle alterations of CXCR4
and MAPT may predispose to regionally specific brain
degeneration in later life. Though we found no evidence
of altered expression of known microglial markers within
human neurodegenerative brains, we found that CXCR4
expression was significantly upregulated in PSP, FTD, and
PD brains. Furthermore, within the tauopathy mouse
model, we found a strong association between CXCR4 and
TMEM119 and AIF1 within the hippocampus. Addition-
ally, across all evaluated regions, we found a strong rela-
tionship between microglia and inflammation related
genes, namely CCR5 and TLR2 expression and TMEM119
and AIF1 expression. Finally, expression of TMEM119
and AIF1 was markedly elevated predominantly within the
hippocampus in Tau-P301L mouse model expression
data. Thus, results from the Tau-P301L mouse model
data suggest that upregulated CXCR4 expression observed
during age-associated neurodegeneration may be related
to inflammatory mechanisms.
Our study benefits from its use of multiple well-
validated GWAS datasets and its integration of multiple
information modalities ranging from population level
genetic data to RNA expression in mouse models of
tauopathy. Our study used GWAS data composed of
common SNPs and thereby cannot inform the potential
role that rare variation may play as a risk factor for PSP,
PD, and FTD. A limitation of our study is that we do not
have records indicating which GWAS SNPs were directly
genotyped vs. imputed, limiting our ability to assess the
quality of SNP ascertainment in our cohorts. Further,
while we demonstrated that rs749873 modified CXCR4
expression in human blood, we were unable to test for an
eQTL in a large dataset of control human brains. Given
differences in sample size between the two tissue types,
this could be a function of statistical power. Indeed,
previous work has shown that many eQTLs are shared
across tissues and that ability to detect an eQTL varies
with sample size30.
In conclusion, by integrating large neurodegenerative
GWAS data with gene expression data from neurode-
generative diseases and transgenic mouse models, our
multi-modal findings indicate that CXCR4 is associated
with PSP and PD neurodegeneration. Clinically, our
results provide additional evidence that immune and
microglial dysfunction contribute to the pathophysiology
in PSP, PD, and FTD. These findings have important
implications for future work focused on monitoring
microglial activation as a marker of disease progression
and on developing anti-inflammatory therapies to modify
disease outcomes in patients with neurodegenerative
diseases.
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